Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Publication

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Journal Paper/Review - Feb 11, 2023

Jensen Anders Boisen, Renström Frida, Aczel Stefan, Folie Patrick, Biraima Magdalena, Beuschlein Felix, Bilz Stefan

Citation

Jensen A, Renström F, Aczel S, Folie P, Biraima M, Beuschlein F, Bilz S. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Obes Surg 2023:1-9.

Type

Journal Paper/Review (English)

Journal

Obes Surg 2023

Publication Date

Feb 11, 2023

Issn Electronic

1708-0428

Pages

1-9

Brief description/objective

Weight regain after bariatric surgery occurs in up to a third of patients and reduces treatment-associated health benefits. The efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RA) for treatment of type 2 diabetes mellitus and obesity is well established, but their role in the treatment of weight regain after bariatric surgery remains to be defined.